Literature DB >> 15113882

RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Philip J Budge1, Yeqiang Li, Judy A Beeler, Barney S Graham.   

Abstract

Large polyanionic molecules, such as sulfated polysaccharides (including soluble heparin and dextran sulfate), synthetic polyanionic polymers, and negatively charged proteins, have been shown to broadly inhibit several enveloped viruses. We recently reported the antiviral activity of a peptide derived from amino acids 77 to 95 of a potential binding partner of respiratory syncytial virus F protein (RSV F), the GTPase RhoA. A subsequent study with a truncated peptide (amino acids 80 to 94) revealed that optimal antiviral activity required dimerization via intermolecular disulfide bonds. We report here that the net negative charge of this peptide is also a determining factor for its antiviral activity and that it, like other polyanions, inhibits virus attachment. In a flow cytometry-based binding assay, peptide 80-94, heparin, and dextran sulfate inhibited the attachment of virus to cells at 4 degrees C at the same effective concentrations at which they prevent viral infectivity. Interestingly, time-of-addition experiments revealed that peptide 80-94 and soluble heparin were also able to inhibit the infectivity of a virus that had been prebound to cells at 4 degrees C, as had previously been shown for dextran sulfate, suggesting a potential role for postattachment effects of polyanions on RSV entry. Neutralization experiments with recombinant viruses showed that the antiviral activities of peptide 80-94 and dextran sulfate were diminished in the absence of the RSV attachment glycoprotein (G). Taken together, these data indicate that the antiviral activity of RhoA-derived peptides is functionally similar to that of other polyanions, is dependent on RSV G, and does not specifically relate to a protein-protein interaction between F and RhoA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113882      PMCID: PMC400344          DOI: 10.1128/jvi.78.10.5015-5022.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  Polyanions--a lost chance in the fight against HIV and other virus diseases?

Authors:  M Lüscher-Mattli
Journal:  Antivir Chem Chemother       Date:  2000-07

2.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

3.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Recent progress in antiviral chemotherapy for respiratory syncytial virus infections.

Authors:  S Shigeta
Journal:  Expert Opin Investig Drugs       Date:  2000-02       Impact factor: 6.206

5.  The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate.

Authors:  S A Feldman; S Audet; J A Beeler
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 6.  An update on respiratory syncytial virus antiviral agents.

Authors:  G A Prince
Journal:  Expert Opin Investig Drugs       Date:  2001-02       Impact factor: 6.206

7.  Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans.

Authors:  Isidoro Martínez; José A Melero
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

8.  Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.

Authors:  S Lederman; R Gulick; L Chess
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

9.  Characteristics of fusion of respiratory syncytial virus with HEp-2 cells as measured by R18 fluorescence dequenching assay.

Authors:  N Srinivasakumar; P L Ogra; T D Flanagan
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

10.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.

Authors:  L N Callahan; M Phelan; M Mallinson; M A Norcross
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  8 in total

1.  Engineering and expression of a RhoA peptide against respiratory syncytial virus infection in plants.

Authors:  Benita Ortega-Berlanga; Konstantin Musiychuk; Yoko Shoji; Jessica A Chichester; Vidadi Yusibov; Omar Patiño-Rodríguez; Daniel E Noyola; Ángel G Alpuche-Solís
Journal:  Planta       Date:  2015-10-16       Impact factor: 4.116

2.  Lipopolysaccharide-induced lung injury involves the nitration-mediated activation of RhoA.

Authors:  Ruslan Rafikov; Christiana Dimitropoulou; Saurabh Aggarwal; Archana Kangath; Christine Gross; Daniel Pardo; Shruti Sharma; Agnieszka Jezierska-Drutel; Vijay Patel; Connie Snead; Rudolf Lucas; Alexander Verin; David Fulton; John D Catravas; Stephen M Black
Journal:  J Biol Chem       Date:  2014-01-07       Impact factor: 5.157

3.  Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F.

Authors:  Jason S McLellan; Man Chen; Jung-San Chang; Yongping Yang; Albert Kim; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

4.  Protein kinase C-alpha activity is required for respiratory syncytial virus fusion to human bronchial epithelial cells.

Authors:  Homero San-Juan-Vergara; Mark E Peeples; Richard F Lockey; Shyam S Mohapatra
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

Authors:  Kelly Huang; Len Incognito; Xing Cheng; Nancy D Ulbrandt; Herren Wu
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

6.  Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane.

Authors:  Wei Tang; Manmei Li; Yujun Liu; Ning Liang; Zhu Yang; Yanxiang Zhao; Shuai Wu; Sangwei Lu; Yaolan Li; Fenyong Liu
Journal:  FASEB J       Date:  2018-12-20       Impact factor: 5.834

7.  Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein.

Authors:  Morgan S A Gilman; Syed M Moin; Vicente Mas; Man Chen; Nita K Patel; Kari Kramer; Qing Zhu; Stephanie C Kabeche; Azad Kumar; Concepción Palomo; Tim Beaumont; Ulrich Baxa; Nancy D Ulbrandt; José A Melero; Barney S Graham; Jason S McLellan
Journal:  PLoS Pathog       Date:  2015-07-10       Impact factor: 6.823

8.  Biopolymeric nano/microspheres for selective and reversible adsorption of coronaviruses.

Authors:  Justyna Ciejka; Karol Wolski; Maria Nowakowska; Krzysztof Pyrc; Krzysztof Szczubiałka
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2017-03-06       Impact factor: 7.328

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.